Kornimate/medical-research-clean huggingface dataset:
simvastatin and metformin in chronic periodontitis

Conditions: Chronic Periodontitis

Summary: this randomized controlled clinical trial compares efficacy of 1.2% simvastatin with 1% metformin in chronic periodontitis subjects.

aim: to compare the efficacy of locally delivered 1.2% smv gel and 1% mf gel in treatment of intrabony defects in chronic periodontitis subjects and compare it with placebo gel. methods: ninety subjects were categorized into three treatment groups: 1.2% simvastatin (smv), 1% metformin (mf) and placebo gel after scaling and root planning (srp). clinical parameters were recorded at baseline, 3, 6 and 9 months; they included plaque index (pi), modified sulcus bleeding index (msbi), pocket probing depth (ppd), and clinical attachment level (cal). radiologic assessment of intra bony defect (ibd) and percentage defect depth reduction (ddr%) was done at baseline, 6 months and 9 months interval using computer-aided software results: mean ppd reduction and mean cal gain was found to greater in smv group than mf and placebo group at all visits. the ddr% was greater in smv group as compared to mf and placebo group. conclusion: there was greater decrease in msbi and ppd and more cal gain with significant ibd depth reduction at the sites treated with smv and mf as an adjunct to srp in chronic periodontitis subjects with intrabony defects as compared to placebo. the effect was greater in case of smv group, however there was no significant defect depth reduction as compared to mf.

Eligibility criteria:
inclusion criteria: * systemically healthy subjects * pocket depth ≥ 5 mm * clinical attachment level ≥ 4 mm and vertical bone loss ≥ 3 mm on intraoral periapical radiographs, with no history of periodontal therapy in the last 6 months exclusion criteria: * subjects allergic to mf or smv * those on systemic mf or smv therapy * subjects with aggressive periodontitis * immunocompromised subjects * use of tobacco in any form, alcoholics * lactating and pregnant females

Keywords: simvastatin, metformin, chronic periodontitis
comparison between modified bass and horizontal brushing techniques

Conditions: Tooth Plaque

Summary: the goal of this observational study is to determine mean plaque scores to compare the effectiveness after using modified bass and horizontal brushing technique in undergraduate dental students. the main question\[s\] it aims to answer are: * modified bass method is less effective than the horizontal brushing technique for plaque removal in undergraduate dental students * modified bass method is more effective than the horizontal brushing technique for plaque in undergraduate dental students. participants will check plaque scores with the help of probe and disclosing agents after applying both techniques in a separate quadrant on the same subject. researchers will compare modified bass and a horizontal brushing technique to see which one is reliable and more effective.


Eligibility criteria:
inclusion criteria: * dental students between the ages of 19-24; irrespective of gender * informed consent exclusion criteria: * students undergoing orthodontic treatment * students having periodontal pocket * students who underwent scaling less or equal to 3 months ago

Keywords: toothbrushing technique modified bass method horizontal brushing technique
prevalence of sars-cov-2 in conjunctival swab samples among patients with conjunctivitis during the covid-19 pandemic

Conditions: Conjunctivitis; SARS-CoV-2; COVID-19; Ocular Infection, Viral; Ocular Inflammation

Summary: severe acute respiratory syndrome coronavirus 2 (sars-cov-2) is a newly identified, highly contagious rna virus causing respiratory infectious disease, coronavirus disease 2019 (covid-19). conjunctivitis has been reported as a rare finding of the disease, and preliminary studies showed that the virus rna could be detected in ocular secretions using polymerase chain reaction (pcr) assays when conjunctivitis present. this study aims to estimate the proportion of sars-cov-2 associated conjunctivitis among patients with suspected viral conjunctivitis presented to the ophthalmology clinics of wilmer eye institute during the covid-19 pandemic. the investigators also aim to identify whether sars-cov-2 associated conjunctivitis is an isolated finding or an early sign of covid-19.


Eligibility criteria:
inclusion criteria: * age 18 years old or older * willingness to participate * presents with red eye complaint exclusion criteria: * adults lacking capacity to consent * adults with special needs due to physical, medical, developmental or cognitive conditions

Keywords: conjunctivitis sars-cov-2 covid-19 ocular infection viral conjunctivitis ocular inflammation conjunctival swab pcr
electromiographic analysis of the quadriceps after trauma

Conditions: Leg Injury; Bone Fracture

Summary: the lower limb is the region most affected by fractures in the human body. the magnitude of the trauma can cause injuries to structures adjacent to the fracture, promoting joint instability and consequently predisposition to osteoarthritis. the treatment of fractures can be performed conservatively or surgically, and one of the consequences of the surgery is arthrogenic muscle inhibition, which presents itself as a marked muscle weakness due to inhibition of the central nervous system that prevents adequate muscle activation. however, recruiting the quadriceps is the most commonly used goal to determine the patient's return to activities. physiotherapy has several resources for the functional activation of the quadriceps muscle, such as neuromuscular electrostimulation (nmes), verbal command of muscle activation and neuromatrix techniques. thus, the objective of this study will be to analyze, by means of electromyography, the myoelectric activity of the quadriceps muscle in individuals undergoing physical therapy intervention, affected by some fracture of the lower limb.


Eligibility criteria:
inclusion criteria: * trauma in lower member intervention exclusion criteria: * neuromuscular disease
mk0507a clinical study in patients with glaucoma and ocular hypertension (0507a-149)(completed)

Conditions: Glaucoma

Summary: the clinical study compares safety and efficacy of mk0507a (dorzolamide 1.0% / timolol 0.5%) with 1) timolol 0.5% and with 2) concomitant therapy with dorzolamide 1.0% / timolol 0.5% in patients with glaucoma and ocular hypertension.


Eligibility criteria:
inclusion criteria: * patients with glaucoma and ocular hypertension exclusion criteria: * history of ocular surgery within 3 months * administration contradiction to timolol and dorzolamide
poly-l/d-lactide implant (regjoint) versus tendon interposition for trapeziometacarpal inflammatory arthritis: a 15-year follow-up

Conditions: Rheumatoid Arthritis (RA)

Summary: this is a late (about 15 years) follow-up study of a randomized prospective clinical study originally conducted as a collaboration of the rheumatism foundation hospital, heinola, finland and päijät-häme central hospital, lahti finland. for the original study thirty-five patients with symptomatic end-stage inflammatory arthritis of the trapeziometacarpal joint were recruited. all patients signed written informed consent and were randomised to undergo surgery using either tendon interposition or poly-l-d-lactic acid implant interposition arthroplasty of said joint. the study was approved by the päijät-häme hospital district ethics committee. results of up to two years of follow-up have been published previously (doi: 10.3109/2000656x.2012.669202). for the current study all patients included in the final data analysis of the original study are to be contacted for a late follow-up using the same metrics used in the original study (hand pain and hand function rated on a visual analogue scale, hand strenght measurements, hand range of motion measurements, hand dexterity tests and tests simulating hand function in activities of daily living). additionally outcomes will be assessed using the patient rated wrist/hand evaluation and quickdash clinical outcome measurement scores. collected follow-up data will be statistically analyzed and a summary will be published in a peer-reviewed scientific journal.


Eligibility criteria:
inclusion criteriria: patients of the study the results of which are reported in the following article: doi: 10.3109/2000656x.2012.669202 inclusion criteria for the original study: * symptomatic end- stage inflammatory arthritis of the trapeziometacarpal joint * trapeziometacarpal arthroplasty at rheumatism foundation hospital, heinola between january 2004 and december 2005 * signed written informed consent exclusion criteria for the original study: -age less than 18 years
comparison of taf and tdf in preventing mother-to-child transmission of hbv in pregnancies with high viral loads

Conditions: Hepatitis B

Summary: the main objective of this study is to compare the mother-to-infant transmission rates of hepatitis b between pregnant women receiving treatment with tenofovir alafenamide and those receiving treatment with tenofovir disoproxil fumarate, after administering the hepatitis b vaccine and hepatitis b immunoglobulin to their infants at birth. investigators define the mother-to-infant transmission rate of hepatitis b as the proportion of infants who are hbsag positive and have serum hbv dna \>20 iu/ml at 28 weeks of age among all live births in the experimental group. additionally, this study will also compare the incidence of congenital defects/malformations in infants born to mothers treated with tenofovir alafenamide and tenofovir disoproxil fumarate during the perinatal period to assess drug safety.

see summary

Eligibility criteria:
inclusion criteria: 1. pregnant women aged between 20 and 40 years old 2. pregnancy duration between 20 to 28 weeks (screening for eligible patients can start from the 20th week of gestation) 3. clinically diagnosed with compensated chronic hepatitis b, hbsag positive for more than 6 months, with clinical history, signs, and test results consistent with compensated chronic hepatitis b 4. hbsag and hbeag positive in maternal serum during screening 5. pcr testing shows maternal serum hbv dna levels exceeding 200,000 iu/ml 6. subjects voluntarily agree to undergo treatment according to the study design's drug treatment plan and all other research requirements, and patients consent to strictly avoid pregnancy within 28 weeks postpartum 7. patients and their husbands (the biological parents of the child) understand the risks and voluntarily participate in the study. the mother must participate voluntarily and sign a written informed consent document before participating in the study. exclusion criteria: 1. creatinine clearance \< 100 ml/min (calculated using the cockcroft-gault method based on serum creatinine and ideal body weight), or hypophosphatemia (below normal range). 2. history of adverse renal reactions induced by adefovir or history of adefovir resistance. 3. meeting one of the following criteria: hemoglobin \ 5 times the upper limit of normal, total bilirubin \> 20 mg/l, albumin \< 25 g/l, abnormal levels of creatinine or urea nitrogen. 4. pregnant women with a history of miscarriage, history of giving birth to a child with congenital malformations, or history of fetal infection with hepatitis b virus. 5. the biological father of the current pregnancy has chronic hepatitis b. 6. the investigator assesses that the subject has significant kidney, cardiovascular, pulmonary, or neurological diseases that affect their participation in the study.
a clinical trial to evaluate the tolerability and pharmacokinetics of ckd-348(3)

Conditions: Hypertension and Dyslipidemia

Summary: a clinical trial to evaluate the pharmacokinetics and tolerability of ckd-348(3)

an open label, randomized, single dose, 2-sequence, 4-period, cross-over clinical trial to evaluate the pharmacokinetics and tolerability of ckd-348(3) with coadministration of ckd-828, d097 and d337 in healthy adult volunteers

Eligibility criteria:
inclusion criteria: 1. healthy adult volunteers aged ≥ 19 years 2. weight ≥50kg (man) or 45kg (woman), with calculated body mass index (bmi) of 18 to 30 kg/m2 3. those who meet the blood pressure criteria during screening tests: * systolic blood pressure: 90 to 139 mmhg * diastolic blood pressure: 60 to 89 mmhg 4. those who have no congenital diseases or chronic diseases and have no abnormal symptoms or findings. 5. those who are eligible for clinical trials based on laboratory (hematology, blood chemistry, serology, urology) and 12-lead ecg results at screening. 6. those who agree to contraception during the participation of clinical trial. 7. individuals who voluntarily decide to participate and agree to comply with the cautions after fully understand the detailed description of this clinical trial. exclusion criteria: 1. those who received investigational products or participated in bioequivalence tests within 6 months before the first administration of clinical trial drugs. 2. those who take barbiturate and any related drugs which may cause induction or inhibition of drug metabolism within 1 month before the first administration of investigational products. 3. those who donated whole blood or apheresis within 8 weeks or 4 weeks respectfully, or received blood transfusion within a month. 4. those who have a history of gastrointestinal surgery except simple appendectomy and hernia surgery. 5. those who exceed an alcohol and cigarette consumption than below criteria * alcohol: man_21 glasses/week, woman_14 glasses/week (1 glass: soju 50ml, wine 30ml, or beer 250ml) * smoking: 20 cigarettes/day 6. those who have any history of diabetic mellitus, nephropathy, biliary obstruction, shock, angioedema, cardiac insufficiency, dihydropyridine sensitivity, unstable angina, hypothyroidism. 7. those who have genetic problems such as galactose intolerance, lapp lactose deficiency or glucose-galactose malabsorption. 8. those who are deemed insufficient to participate in this clinical study by investigators. 9. woman who are pregnant or breastfeeding.
impact of respiratory viral infections in infants with cystic fibrosis.

Conditions: Cystic Fibrosis; Respiratory Viral Infection

Summary: respiratory viral infections (rvi) are particularly frequent in young children. old data mention the deleterious role of some viruses such as the respiratory syncytial virus in young children with cystic fibrosis (cf). however, recent epidemiological data on rvi in cf children are rare and the impact of most frequent viruses such as human rhinoviruses is usually not correctly evaluated. the aim of this study is to assess the frequency of lower and upper rvi during a 1 year follow-up in cf infants and to evaluate the impact of rvi at a clinical, microbiological and therapeutic level. our hypothesis is that frequent and/or clinically severe rvis have the worst impact in the short term and without any particular link with a specific virus as previously described.


Eligibility criteria:
inclusion criteria: - infant \<24 months with cystic fibrosis exclusion criteria: - patient \>24 months

Keywords: cystic fibrosis viruses respiratory viral infection children
smoking increases the risk of postoperative wound complications: a propensity score-matched cohort study

Conditions: Wound Complication; Smoking; Postoperative Complications

Summary: cigarette smoking is associated with surgical complications, including wound healing and surgical site infection. however, the association between smoking status and postoperative wound complications is not completely understood. our objective is to investigate the effect of smoking on postoperative wound complications for major surgeries.

smoking at the time of surgery is recognized as a risk factor for cardiovascular, respiratory, and wound-related perioperative complications. wound-related complications can prolong hospital stays, increase hospital resource utilization, and pose an obvious threat to patient recovery. a brief statement on perioperative smoking cessation about smoking impacting wound healing was published by the american society of anesthesiologists' task force on smoking cessation. recently, a consensus statement on perioperative smoking cessation by society for perioperative assessment and quality improvement (spaqi) mentioned that smoking cessation should be done as soon as practicable with surgical scheduling. more extended abstinence is associated with lower rates of wound healing complications. several studies have described smoking harms wound healing in specific operations, such as plastic surgery, breast surgery, gastrointestinal surgery, and hip surgery. they found surgical site infection and wound delayed healing more frequently in smokers. but in a few small studies and some surgery, conflicting results were found. besides, risk factors associated with wound complications include infection, smoking, aging, malnutrition, immobilization, diabetes, vascular disease, and immunosuppressive therapy. this study aims to determine the impact of smoking on wound complications for all kinds of major surgeries. to clarify the risks, our study uses the updated national surgical quality improvement program (nsqip) database to find if patients who were active smokers are more likely to have wound-related complications postoperatively. we hypothesized that the active smoking population will have increased infectious complications and wound dehiscence compared with the nonsmoking population.

Eligibility criteria:
inclusion criteria: * from nsqip dataset, patients with complete information for baseline parameters and without preoperative open wound infections exclusion criteria: * incomplete information of baseline parameters, and with preoperative wound infection

Keywords: smoking; postoperative wound complications
effect of saccharomyces cerevisiae on the symptoms of irritable bowel syndrome

Conditions: Irritable Bowel Syndrome

Summary: the main purpose of this study is the effect of the probiotic yeast saccharomyces cerevisiae cncm i-3856 on abdominal pain or intestinal discomfort in patients presenting with the irritable bowel syndrome (ibs)


Eligibility criteria:
inclusion criteria: * ibs subject meeting the rome iii criteria , with a discomfort or pain present more than 1 day per week in whom organic causes of their symptoms have been excluded * ibs-c with less than 3 complete spontaneous bowel movements/week * ibs-d with at least 2 or more days/week one stool which has consistency of type 6 or 7 bristol stool score * subject able of and willing to comply with the protocol and to give their written informed consents exclusion criteria: * history of chronic gastrointestinal disorders * history of lactose intolerance * history of gluten intolerance * treatment able to influence ibs, modifying intestinal sensitivity and motility (antidepressants,opioid, narcotic analgesics) * eating disorders * pregnancy in progress
treatment of refractory gout with acth or methylprednisolone

Conditions: Gout

Summary: to clarify the therapeutic effect and safety evaluation of acth in refractory gouty arthritis and special population, and to explore its mechanism of action.

when patients with acute gout have multiple comorbidities and complications , traditional treatment methods are often contraindicated . from the current clinical research evidence , we have seen the non-inferior effect of acth on glucocorticoids and non-steroidal anti-inflammatory drugs in the treatment of acute gout , as well as the good safety and extensive anti-inflammatory effect in addition to efficacy . therefore , we designed this study to update and improve the treatment of acute gout attacks , and to try to clarify the mechanism of action .

Eligibility criteria:
inclusion criteria: * (123 items and 1 item from 4-7 are met simultaneously) : 1. meet the 2015 acr/eular classification diagnostic criteria for gout 2. acute gouty arthritis 3. age ≥18 4. repeated attacks and prolonged pain (more than 1 month); 5. poor response or intolerance to colchicine or nsaids; 6. liver and kidney dysfunction; 7. old age; exclusion criteria: * 1) history of gastrointestinal bleeding and active ulcer 2) the application history of glucocorticoids and acth in 1 month before screening 3) pregnancy and lactation 4) drug and alcohol abuse 5) malignant tumor (treated or untreated within 5 years) 6) mental illness inability to communicate or have language barriers and inability to fully understand and cooperate 7) negligent compensatory heart failure, unstable angina pectoris, stroke, transient ischemic attack, myocardial infarction, and severe arrhythmia occurred within 6 months 8) the investigator did not consider it appropriate to participate in the study
continuous glucose monitoring for women with gestational diabetes

Conditions: Gestational Diabetes

Summary: there are a few ongoing large randomized controlled trials (rct's) on continuous glucose monitoring (cgm) in women with gestational diabetes (gdm) powered for pregnancy outcomes. however, none of these studies included women diagnosed with early gdm. the cordelia trial is a belgian open-label multi-centric rct with 14 centers in women with gdm (including both early and late gdm). women will be randomized 1/1 to either treatment with cgm (intervention group, freestyle libre 3) or continue with self-monitoring of blood glucose (smbg) with glucometer in line with normal routine (control arm). the study ends at the postpartum oral glucose tolerance test (ogtt 6-24 weeks postpartum) to screen for glucose intolerance.

at diagnosis of gdm, women will receive education on the management of gdm with lifestyle and need to monitor glucose with smbg. within one week of gdm diagnosis, all participants will be asked to use a blinded cgm (freestyle libre pro iq,) during a run-phase. women randomized to the control arm, will be asked to intermittently wear a blinded cgm sensor (freestyle libre pro iq) during 14 days at least two time points in pregnancy (at 31.0-33.6 weeks and between 36.0-38.6 weeks). for women diagnosed with early gdm (\<20 weeks), blinded cgm will be needed 3 times in pregnancy with a first time at 20.0-23.9 weeks. women randomized to the intervention arm will be recommended tu use the rt-cgm (freestyle libre 3) till the delivery. in line with normal routine, a 75g ogtt will be performed between 6-24 weeks postpartum to screen for glucose intolerance. participants will be asked to also wear a blinded cgm (freestyle libre pro iq) at this last study visit.

Eligibility criteria:
inclusion criteria: * at least 18 years of age at the time of signing the informed consent form (icf) * singleton pregnancy * diagnosed with gestational diabetes before 29.6 weeks of pregnancy * needs to be able to understand and speak dutch, french or english. * have email access exclusion criteria: * patient has a history of type 2 or type 1 diabetes, or presence of auto-immune antibodies for type 1 diabetes * a physical or psychological disease likely to interfere with the conduct of the study (based on the evaluation by the treating physician). * use of medication with significant impact on glycemia (such as high dose glucocorticoids and diabetes medication such as metformin) * participation in an interventional trial with an investigational medicinal product or device * multiple pregnancy * history of bariatric surgery * known allergy to the adhesives used with the continuous glucose monitoring

Keywords: gestational diabetes continuous glucose monitoring early gestational diabetes